List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Avivia BV
Eagle Pharmaceuticals Inc
Eli Lilly and Co
Endece LLC
EndoCeutics Inc
Helixmith Co Ltd
Karo Pharma AB
Kissei Pharmaceutical Co Ltd
MEI Pharma Inc
Oasmia Pharmaceutical AB
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles
acolbifene + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dehydrodiconiferyl alcohol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize ER-Beta for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erteberel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estradiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfestrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-3944 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-9520 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Loseasonique - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize ESR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ESR2 for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Dormant Products
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Discontinued Products
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones
Featured News & Press Releases
Dec 03, 2020: AstraZeneca presents new data on fulvestrant at the 2020 San Antonio Breast Cancer Symposium (SABCS)
May 04, 2020: Eagle Pharmaceuticals advances novel and proprietary formulation of Fulvestrant product candidate EA-114; company to request additional meeting with U.S. Food and Drug Administration
Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate
Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer
Mar 27, 2019: Combo better for HR+ breast cancer patients
Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant
Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy
Oct 04, 2018: Mayo researchers identify potential new treatment for subset of women with triple-negative breast cancer
Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
Dec 11, 2017: AstraZeneca's Faslodex Rejects For Use Within NHS Scotland
Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib
Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Avivia BV, 2021
Pipeline by Eagle Pharmaceuticals Inc, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Endece LLC, 2021
Pipeline by EndoCeutics Inc, 2021
Pipeline by Helixmith Co Ltd, 2021
Pipeline by Karo Pharma AB, 2021
Pipeline by Kissei Pharmaceutical Co Ltd, 2021
Pipeline by MEI Pharma Inc, 2021
Pipeline by Oasmia Pharmaceutical AB, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021

Companies Mentioned
• AstraZeneca Plc
• Avivia BV
• Eagle Pharmaceuticals Inc
• Eli Lilly and Co
• Endece LLC
• EndoCeutics Inc
• Helixmith Co Ltd
• Karo Pharma AB
• Kissei Pharmaceutical Co Ltd
• MEI Pharma Inc
• Oasmia Pharmaceutical AB